Undisclosed B-cell surface antigen

The term "Undisclosed B-cell surface antigen" is a placeholder designation used in pharmaceutical pipelines and clinical trial registries to refer to a proprietary protein target expressed on the surface of B-lymphocytes. Because the specific identity of the molecule is withheld for competitive or intellectual property reasons, its exact biological function cannot be definitively characterized; however, it is generally involved in B-cell signaling, development, or survival. In a therapeutic context, these antigens are targeted by monoclonal antibodies, bispecific antibodies, or CAR-T cells to treat B-cell malignancies such as leukemia and lymphoma, or autoimmune disorders. Once the drug candidate reaches a certain stage of clinical development, the specific target (e.g., CD19, CD20, CD22, or BCMA) is typically revealed to the scientific community.

Other names

Undisclosed B-cell antigenProprietary B-cell target

The mechanism of action depends on the specific undisclosed molecule, but typically involves antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or delivery of a cytotoxic payload via an antibody-drug conjugate (ADC).